Eden Biodesign and Stealthyx Therapeutics Ltd sign deal to develop enhanced treatment for rheumatoid arthiritis.

Liverpool, UK; 26 February 2008: Eden Biodesign Ltd, one of the UK's leading contract bio manufacturers and Stealthyx Therapeutics Ltd, a London based biotechnology company, announced today that they have entered into an agreement to develop and produce Stealthyx's lead therapeutic candidate that the company is evaluating for treatment of a range of inflammatory diseases including rheumatoid arthritis.

The product will incorporate Stealthyx Therapeutics' proprietary Prothyx technology that has been developed by Professor Yuti Chernajovsky at Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London. Prothyx harnesses the properties of a naturally occurring peptide to confer stability and disease targeting biological therapeutics resulting in improved efficacy and side effect profile.

Dr Crawford Brown, CEO, Eden Biodesign commented: "We are delighted to work with Stealthyx Therapeutics on the development of this new class of biologics. We have the expertise in product development that is necessary to deliver such novel therapeutics to the market."

"We are very pleased to work with Eden Biodesign on the development of this innovative product said Professor Yuti Chernajovsky. The project will be executed at Eden's state-of-the art facility in Liverpool headed by a very experienced product development team. Working with Eden will accelerate the clinical development of Stealthyx Therapeutics' products and their transition from research laboratories to patients.

Ends

For further information contact:
Maria Patey, DeFacto Communications Ltd
+44 (0)20 7861 3838
Email m.patey@defacto.com

Professor Yuti Chernajovsky, Stealthyx Therapeutics Ltd
Tel: +44 (0)207 882 6122
Email: yuti.chernajovsky@stealthyx.com

Notes to editors:
Stealthyx Therapeutics Ltd

1. Stealthyx Therapeutics Ltd has been established to exploit the intellectual property developed by Professor Yuti Chernajovsky at Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London. The Company's technology platform, Prothyx, is underpinned by extensive research programmes over many years, including specific work funded by the Multiple Sclerosis Society. Stealthyx has to date secured funding from the Kinetique Biomedical Seed fund and a University Translational Award by The Wellcome Trust.

Stealthyx will focus on the development of the Prothyx technology platform as a vehicle for drug delivery. In the first instance this will be applied to protein therapeutics, and work to validate this application of the technology is currently well underway. With the recent investment from The Wellcome Trust, Stealthyx is expanding the applications of the Prothyx platform to include small biologically active peptide molecules. For further information visit www.stealthyx.com

2. Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com